Cipla shares slip after Keytruda biosimilar deal with Qilu, as competition worries weigh; Morgan Stanley cautious
CiplaThis update concerns Cipla. Read the full report at the source below.
Affected stocks
Neutral1 stockBull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.
Key takeaways
- Concerns Cipla (CIPLA).
- Category: Stocks.
Why it matters
A routine update for Cipla. Use the price and stock snapshot to gauge how the market is responding.















